Elsevier

Human Pathology

Volume 29, Issue 2, February 1998, Pages 175-180
Human Pathology

Original contribution
Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis

https://doi.org/10.1016/S0046-8177(98)90229-5Get rights and content

Abstract

Expression of MET, the c-met-encoded receptor for hepatocyte growth factor, has not been investigated in proliferative biliary diseases of human liver, including hepatolithiasis and cholangiocarcinoma. Comparatively, we analyzed by immunohistochemistry the expression of MET in normal adult human livers (n = 20), normal postnatal preadult livers (n = 21), fetal livers (n = 36), hepatolithiatic livers (n = 32), and intrahepatic cholangiocarcinomas (n = 26). In normal adult livers, obvious MET immunoreactivity was not found in any cell types. In fetal liver, MET was weakly expressed in primitive biliary cells (ductal plate and immature bile ducts) and immature hepatocytes during 8 to 30 gestational weeks but was essentially negative thereafter. In hepatolithiasis, a condition of risk for cholangiocarcinoma development, MET was overexpressed in proliferated biliary cells in 26 of 32 cases (81%). In this nonneoplastic proliferative biliary condition, MET immunoreactivity was observed to be most prominent in the hyperplastic septal and large bile ducts of liver, and in the proliferated peribiliary glands associated with intrahepatic large bile ducts. In intrahepatic cholangiocarcinoma, MET overexpression in neoplastic biliary epithelium was observed in 15 of 26 cases (58%) and correlated with the degree of tumor differentiation, being highest in well-differentiated tumors and relatively low in poorly differentiated tumors. These data show for the first time that overexpression of MET is a common feature of hyperplastic and neoplastic biliary epithelial cells in human liver and suggest that MET/hepatocyte growth factor may be playing an important role in human biliary hyperplasia and in cholangiocarcinogenesis in vivo.

References (39)

  • M Prat et al.

    The receptor encoded by the human c-met oncogene is expressed in hepatocytes, epithelial cells and solid tumors

    Int J Cancer

    (1991)
  • M Ebert et al.

    Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer

    Cancer Res

    (1994)
  • T Furukawa et al.

    Hepatocyte growth factor and met receptor expression in human pancreatic carcinogenesis

    Am J Pathol

    (1995)
  • K Suzuki et al.

    Expression of the c-met proto-oncogene in human hepatocellular carcinoma

    Hepatology

    (1994)
  • Y Nakanuma et al.

    Are hepatolithiasis and cholangiocarcinoma aetiologically related?

  • T Terada et al.

    Histological features and interphase nucleolar organizer regions in hyperplastic, dysplastic and neoplastic epithelium of intrahepatic bile ducts in hepatolithiasis

    Histopathology

    (1992)
  • R Joplin et al.

    Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor

    J Clin Invest

    (1992)
  • K Matsumoto et al.

    Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro

    Hepatology

    (1994)
  • H Shimura et al.

    Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro

    Jpn J Cancer Res

    (1995)
  • Cited by (127)

    • Emerging pathways for precision medicine in management of cholangiocarcinoma

      2020, Surgical Oncology
      Citation Excerpt :

      The biological activity of the MET pathway results in increased cell proliferation and motility. In contrast to the normal adult liver parenchyma, which demonstrates no obvious MET expression in any cell types, MET overexpression has been reported in up to 58% of iCCA and 16% of eCCA patients [27,68]. Nakazawa et al. reported significantly higher c-MET overexpression in iCCA compared with any other BTC [69].

    • Targeting cholangiocarcinoma

      2018, Biochimica et Biophysica Acta - Molecular Basis of Disease
    • Emerging molecular therapeutic targets for cholangiocarcinoma

      2017, Journal of Hepatology
      Citation Excerpt :

      Tumors can harness these processes to promote tumor growth and invasion. MET overexpression occurs in iCCA and correlates with the degree of tumor differentiation.31 An integrated molecular analysis identified two distinct biological classes in iCCA, an inflammation class (38% of iCCAs) and a proliferation class (62% of iCCAs).32

    • Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis

      2017, Surgical Oncology
      Citation Excerpt :

      MET is activated by its ligand HGF, which induces MET kinase catalytic activity and initiates a spectrum of biologic activities collectively known as the invasive growth program. MET overexpression has been associated with increased invasion and poor prognosis in biliary tract cancers, and thus may be helpful as a prognostic biomarker [104,105]. Elevated expression of matrix metalloproteinase (MMP) is known to enhance cancer metastasis.

    View all citing articles on Scopus

    Supported by ROI CA39225 to Alphonse E. Sirica from the National Cancer Institute, National Institutes of Health, Bethesda, MD.

    View full text